Loading clinical trials...
Loading clinical trials...
Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
Conditions
Interventions
Tivantinib (ARQ 197)
Locations
10
United States
Los Angeles, California, United States
Orlando, Florida, United States
Indianapolis, Indiana, United States
St Louis, Missouri, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Start Date
February 2, 2010
Primary Completion Date
November 30, 2011
Completion Date
November 30, 2011
Last Updated
April 6, 2021
Lead Sponsor
Daiichi Sankyo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions